Benefits of Hysteroscopy Prior to Performing a Cycle of in Vitro Fertilization/Intracytoplasmic Sperm Injection


Original post, click here
Primary Outcome Measures:

  • Percentage of biochemical, clinical, on-going pregnancy and livebirth of IVF treatment [ Time Frame: 12 months ]

    Percentage of biochemical, clinical, on-going pregnancy and livebirth of IVF treatment comparing both groups.

Secondary Outcome Measures:

  • Percentage of endocervical canal and uterine cavity pathology and the impact of treatment of these pathologies. [ Time Frame: 12 months ]

    Percentage of endocervical canal and uterine cavity pathology and the impact of treatment of these pathologies in the rate of pregnancy and livebirth.

  • Rate of hysteroscopy tolerance [ Time Frame: 1 month. ]

    The tolerance of the procedure was evaluate in the patients randomized to the group I of the study.

  • Hysteroscopy complication rate. [ Time Frame: 2 months ]

    We evaluate the complication of the hysteroscopy during and after the procedure. Includes blooding, infections, uterine perforation, etc.

This is a prospective randomized open-label trial. Women scheduled for their first or second IVF/ICSI cycle and with no abnormality detected in transvaginal ultrasound examination, were randomized to two groups. In the first group (group I) 31 patients underwent hysteroscopy examination before IVF cycle while in the second group (group II) 37 patients underwent direct cycle without previous hysteroscopy. Then IVF cycle was performed with habitual protocol. Beta Corionic Gonatropic hormone (BhCG) test two weeks after embryo transfer was done. If test was positive, patients were followed up for detection pregnancy by transvaginal ultrasound two weeks later. Another transvaginal ultrasound at 12 weeks of gestation was done to confirm ongoing pregnancy. Biochemical pregnancy, implantation, on-going pregnancy and livebirth rates were compared in both groups.

Miscarriage, complications rate and hysteroscopy tolerability were also analyzed.